Macau SupraScience Biomedicine Co., Ltd. is a technology platform company focusing on the development of revolutionary cell-based drug delivery systems for targeted therapy, and providing state-of-the-art technical and medical consultancy services to the biomedical industry. The team developed the world’s first technology of "SupraCell" that may provide an efficient live cell-drug delivery platform by using supramolecular technology for highly targeted therapy of inflammatory diseases and cancers. This technology allows rapid preparation of personalized medicine from the patient's own blood cells in combination with the first-line drugs within a matter of a couple of days for rapid, precise disease treatment. The first pipelines include medicines for melanoma, acute pneumonia, and atherosclerosis, which we have completed preclinical evaluations.
